159 related articles for article (PubMed ID: 25933594)
1. Boronic acid-containing CXCR1/2 antagonists: Optimization of metabolic stability, in vivo evaluation, and a proposed receptor binding model.
Maeda DY; Peck AM; Schuler AD; Quinn MT; Kirpotina LN; Wicomb WN; Auten RL; Gundla R; Zebala JA
Bioorg Med Chem Lett; 2015 Jun; 25(11):2280-4. PubMed ID: 25933594
[TBL] [Abstract][Full Text] [Related]
2. Boronic acid-containing aminopyridine- and aminopyrimidinecarboxamide CXCR1/2 antagonists: Optimization of aqueous solubility and oral bioavailability.
Schuler AD; Engles CA; Maeda DY; Quinn MT; Kirpotina LN; Wicomb WN; Mason SN; Auten RL; Zebala JA
Bioorg Med Chem Lett; 2015 Sep; 25(18):3793-7. PubMed ID: 26248802
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2.
Maeda DY; Peck AM; Schuler AD; Quinn MT; Kirpotina LN; Wicomb WN; Fan GH; Zebala JA
J Med Chem; 2014 Oct; 57(20):8378-97. PubMed ID: 25254640
[TBL] [Abstract][Full Text] [Related]
4. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
Planagumà A; Domènech T; Pont M; Calama E; García-González V; López R; Aulí M; López M; Fonquerna S; Ramos I; de Alba J; Nueda A; Prats N; Segarra V; Miralpeix M; Lehner MD
Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598
[TBL] [Abstract][Full Text] [Related]
5. C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists.
Chao J; Taveras AG; Chao J; Aki C; Dwyer M; Yu Y; Purakkattle B; Rindgen D; Jakway J; Hipkin W; Fosetta J; Fan X; Lundell D; Fine J; Minnicozzi M; Phillips J; Merritt JR
Bioorg Med Chem Lett; 2007 Jul; 17(13):3778-83. PubMed ID: 17459706
[TBL] [Abstract][Full Text] [Related]
6. Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases.
Busch-Petersen J
Curr Top Med Chem; 2006; 6(13):1345-52. PubMed ID: 16918453
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
Gonsiorek W; Fan X; Hesk D; Fossetta J; Qiu H; Jakway J; Billah M; Dwyer M; Chao J; Deno G; Taveras A; Lundell DJ; Hipkin RW
J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2.
Kaur M; Singh D
J Pharmacol Exp Ther; 2013 Oct; 347(1):173-80. PubMed ID: 23912333
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.
Dwyer MP; Yu Y; Chao J; Aki C; Chao J; Biju P; Girijavallabhan V; Rindgen D; Bond R; Mayer-Ezel R; Jakway J; Hipkin RW; Fossetta J; Gonsiorek W; Bian H; Fan X; Terminelli C; Fine J; Lundell D; Merritt JR; Rokosz LL; Kaiser B; Li G; Wang W; Stauffer T; Ozgur L; Baldwin J; Taveras AG
J Med Chem; 2006 Dec; 49(26):7603-6. PubMed ID: 17181143
[TBL] [Abstract][Full Text] [Related]
10. The combined CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks neutrophil infiltration, pyrexia, and pulmonary vascular pathology in endotoxemic animals.
Gordon JR; Li F; Zhang X; Wang W; Zhao X; Nayyar A
J Leukoc Biol; 2005 Dec; 78(6):1265-72. PubMed ID: 16204619
[TBL] [Abstract][Full Text] [Related]
11. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor.
Bertini R; Barcelos LS; Beccari AR; Cavalieri B; Moriconi A; Bizzarri C; Di Benedetto P; Di Giacinto C; Gloaguen I; Galliera E; Corsi MM; Russo RC; Andrade SP; Cesta MC; Nano G; Aramini A; Cutrin JC; Locati M; Allegretti M; Teixeira MM
Br J Pharmacol; 2012 Jan; 165(2):436-54. PubMed ID: 21718305
[TBL] [Abstract][Full Text] [Related]
12. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation.
Chapman RW; Minnicozzi M; Celly CS; Phillips JE; Kung TT; Hipkin RW; Fan X; Rindgen D; Deno G; Bond R; Gonsiorek W; Billah MM; Fine JS; Hey JA
J Pharmacol Exp Ther; 2007 Aug; 322(2):486-93. PubMed ID: 17496165
[TBL] [Abstract][Full Text] [Related]
13. Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region.
Aki C; Chao J; Ferreira JA; Dwyer MP; Yu Y; Chao J; Merritt RJ; Lai G; Wu M; Hipkin RW; Fan X; Gonsiorek W; Fosseta J; Rindgen D; Fine J; Lundell D; Taveras AG; Biju P
Bioorg Med Chem Lett; 2009 Aug; 19(15):4446-9. PubMed ID: 19525110
[TBL] [Abstract][Full Text] [Related]
14. Blockade of the chemokine receptor CXCR2 ameliorates adjuvant-induced arthritis in rats.
Barsante MM; Cunha TM; Allegretti M; Cattani F; Policani F; Bizzarri C; Tafuri WL; Poole S; Cunha FQ; Bertini R; Teixeira MM
Br J Pharmacol; 2008 Mar; 153(5):992-1002. PubMed ID: 17891165
[TBL] [Abstract][Full Text] [Related]
15. N,N'-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors.
Nie H; Widdowson KL; Palovich MR; Fu W; Elliott JD; Bryan DL; Burman M; Schmidt DB; Foley JJ; Sarau HM; Busch-Petersen J
Bioorg Med Chem Lett; 2006 Nov; 16(21):5513-6. PubMed ID: 16934456
[TBL] [Abstract][Full Text] [Related]
16. Fluoroalkyl alpha side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists.
Biju P; Taveras AG; Dwyer MP; Yu Y; Chao J; Hipkin RW; Fan X; Rindgen D; Fine J; Lundell D
Bioorg Med Chem Lett; 2009 Mar; 19(5):1431-3. PubMed ID: 19196511
[TBL] [Abstract][Full Text] [Related]
17. 3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists.
Biju P; Taveras A; Yu Y; Zheng J; Chao J; Rindgen D; Jakway J; Hipkin RW; Fossetta J; Fan X; Fine J; Qiu H; Merritt JR; Baldwin JJ
Bioorg Med Chem Lett; 2008 Jan; 18(1):228-31. PubMed ID: 18006311
[TBL] [Abstract][Full Text] [Related]
18. Nicotinamide glycolates antagonize CXCR2 activity through an intracellular mechanism.
Maeda DY; Quinn MT; Schepetkin IA; Kirpotina LN; Zebala JA
J Pharmacol Exp Ther; 2010 Jan; 332(1):145-52. PubMed ID: 19779130
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of murine allergic airway inflammation with a CXCR1/CXCR2 chemokine receptor inhibitor.
Hosoki K; Rajarathnam K; Sur S
Clin Exp Allergy; 2019 Jan; 49(1):130-132. PubMed ID: 30218547
[No Abstract] [Full Text] [Related]
20. The selective CXCR2 antagonist SB272844 blocks interleukin-8 and growth-related oncogene-alpha-mediated inhibition of spontaneous neutrophil apoptosis.
Glynn PC; Henney E; Hall IP
Pulm Pharmacol Ther; 2002; 15(2):103-10. PubMed ID: 12090783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]